Skip to main content
Results for the CO.27 IROCAS international trial  presented at ESMO

Results for the CO.27 IROCAS international trial presented at ESMO

CO.27 IROCAS was a phase III, multicenter, open-labeled randomized trial comparing the combinations of 5-fluorouracil (5-FU), folinic acid, irinotecan, and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, and 5-FU (mFOLFOX 6) in patients with high-risk stage III colon cancer in the adjuvant setting. The recent ESMO presentation by Dr Bennouna Jaafar, a medical oncologist at Foch Hospital, Suresnes who led the study, showed that adjuvant mFOLFIRINOX triplet chemotherapy did not improve DFS compared with standard doublet mFOLFOX6.

More >>
 
PR22 findings were presented by Dr. Tamim Niazi at the Presidential Symposium at European Society for Medical Oncology (ESMO) 2026 Congress.

Early findings from the PR.22 trial show promise in delaying the spread of high-risk prostate cancer

Interim results from the CCTG PR.22 (DASL-HiCaP ANZUP 1801) clinical trial, has seen a delay in the spread of prostate cancer. The findings were presented by Dr. Tamim Niazi at the Presidential Symposium at European Society for Medical Oncology (ESMO) 2026 Congress.

More >>
 
The first two CCTG led cell therapy trials are now open in Canada

The first two CCTG led cell therapy trials are now open in Canada

CCTG is committed to the evaluation of innovative cell therapy products, strategies to improve cell therapy outcomes and to advancing accessibility for Canadian patients. IND246 study is a phase I trial evaluating increasing dose levels of GCAR1 and IND245 is a trial evaluating the addition of sonrotoclax and zanubrutinib in patients with mantle cell lymphoma.

More >>
 
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

CCTG, EORTC and UK3CR welcome the G7 Leaders’ announcement recognizing cancer as a global priority.

More >>
 

Planned trials

ALC11

Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy

ALC9

Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)

BI4

Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)

CXC3

Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

EN12

RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features

GC1

MiRNA371-Guided MAnagement in Testicular germ cell tumors- MAGMA GCT

HN14

Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC

MA42

No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)

MAC32

Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER+/HER2-neg Breast Cancer with Recurrence Score ≤ 25 (RxFINE-Low)

MD1

Combination Therapy with Luspatercept in Lower Risk Myelodysplasia: A Tier 1 myeloMATCH Substudy

More >>

ME18

Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)

ME19

Adjuvant tebentafusp (IMCgp100) vs obs in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma (ATOM Trial)

SR8

NeoAdjuvant-only or Peri-operative cemiplimab in high-grade localised soft-tissue SARcoma (NAPStAR)

Recently activated

BR39

LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial

More >>

ALC10

Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy

More >>

LYC2

Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

More >>

PAC5

Lanreotide for the Prevention of Postoperative Pancreatic Fistula

More >>

SC31

Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)

More >>
June is National Indigenous History Month and Pride Month

CCTG recognizes June as National Indigenous History Month and Pride Month

June marks both National Indigenous History Month and Pride Month. It is a time to learn about and honour the diverse cultures, histories, and experiences of First Nations, Inuit, and Métis Peoples, and to celebrate the strength, resilience, and contributions of 2SLGBTQI+ communities. It is also an opportunity to reflect on our shared responsibility to advance equitable, inclusive, and culturally safe clinical trial design and conduct.

More >>
 
Patient Represenative Melanie Keats

Welcome to new Patient Represenative Melanie Keats

CCTG would like to welcome Melanie Keats as the new patient representative supporting the Gynecologic Disease Site Committee. Melanie resides in Halifax Nova Scotia and is a a Professor and Associate Research Scholar, Health Populations Research Institute at Dalhousie University as well as a Nova Scotia Health Authority Affiliated Scientist and Co-Director Physical Activity and Cancer (PAC) Lab.

More >>
 
The innovative ME17 melanoma trial has opened to enrollment

The innovative ME17 melanoma trial has opened to enrollment

One of the world’s largest randomized clinical trials, investigating the use of fecal microbiota transplantation (FMT) has opened in Canada.

More >>
 
The new MAC30 trial compares two treatments for early-stage breast cancer in premenopausal women

The new MAC30 trial compares two treatments for early-stage breast cancer in premenopausal women

MAC30 has recently opened in Canada and will compare two commonly used treatment choices for premenopausal women with ER-positive/HER2-negative breast cancer and a low to intermediate risk of recurrence.

More >>